EU Committee Recommended Three New Sogroya Indications
Regulators backed the use of the growth hormone therapy for three additional pediatric conditions.
Updated on Sept. 22, 2026 in Children’s Health
Live Poll
Should regulatory bodies expand approvals for growth hormone therapies in children?
The European Medicines Agency committee recommended Sogroya for the treatment of idiopathic short stature, children failing catch-up growth after being small for gestational age, and Noonan syndrome. This follows a re-examination of an initial opinion issued in May 2026.
Why it matters
Expanding these pediatric indications allows more children with growth disorders to potentially access long-acting, once-weekly hormone therapy. The recommendation comes after regulators reviewed trial data confirming the noninferiority of the treatment compared to traditional daily injections.
The committee recommended three new pediatric indications for Sogroya, which uses a reversible albumin-binding moiety to allow for once-weekly dosing. This follows the 52-week REAL8 trial, which demonstrated noninferiority to daily hormone therapies.
The players
European Medicines Agency
This is the European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
Committee for Medicinal Products for Human Use
This is the body within the European Medicines Agency that is responsible for preparing opinions on questions relating to medicines for human use.
The details
Sogroya, a recombinant human growth hormone analogue, functions by attaching to circulating albumin to extend its half-life. These new recommendations expand on previous approvals for growth hormone deficiency in adults and children.
Timeline
March 2021: Sogroya received initial EU approval for adult growth hormone deficiency.
July 2023: Sogroya received EU approval for pediatric growth hormone deficiency.
May 2026: The committee issued an initial opinion that underwent subsequent re-examination.
September 22, 2026: The CHMP issued a positive opinion for the three new indications.
Late November 2026: European Commission final authorization is expected.
The Big Picture
This recommendation marks the latest step in the European Medicines Agency's authorization process for medicinal products, which requires consistent regulatory scrutiny for long-acting hormone analogues. The positive opinion for these new pediatric indications follows the standard regulatory path established by the agency for assessing new therapy approvals.
The expansion of these indications could simplify treatment for children by reducing the frequency of hormone injections from daily to once weekly. Patients and caregivers should consult with pediatric endocrinologists to determine if these new treatment options are appropriate for their specific diagnosis.
The takeaway
The transition toward long-acting hormone analogues represents a shift in pediatric endocrinology to reduce the burden of daily medical regimens. Families are encouraged to discuss the efficacy of once-weekly options with specialists to ensure consistent treatment adherence.
What happens next
The European Commission is expected to finalize the marketing authorization for the three new pediatric indications in late November 2026.
Further reading
For more information on pediatric treatment standards, visit Children’s Health.
Source note: This article includes information reported by Medscape.
Live Poll
Should regulatory bodies expand approvals for growth hormone therapies in children?
